Bristol Myers Squibb Canada (BMY), Acceleron Pharma (XLRN) Announce Health Canada Approves REBLOZYL, New Class of Treatment for Adult Patients Living With Myelodysplastic Syndromes

Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living With Myelodysplastic Syndromes

REBLOZYL®, an erythroid maturation agent, is the first and only of its kind approved for use in Canada

MONTREAL--(BUSINESS WIRE)-- Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. announced today that Health Canada has approved REBLOZYL® (luspatercept for injection) for the treatment of adult patients with transfusion-dependent anemia requiring at least two RBC red blood cell (RBC) units over 8 weeks resulting from very low-to intermediate-risk myelodysplastic syndromes (MDS) who have ring sideroblasts and who have failed or are not suitable for erythropoietin-based therapy.1 REBLOZYL® represents a new class of treatment for... More